Key result
Previous use of antiplatelet drugs was observed in 41% (642 of 1582) of patients admitted with new or recurrent ischemic stroke.
Why the study?
What proportion of patients presenting with new or recurrent ischemic stroke were already receiving antiplatelet therapy?
Cross-Sectional (n=1,582)
Yes
What proportion of patients presenting with new or recurrent ischemic stroke were already receiving antiplatelet therapy?
A high proportion (41%) of patients presenting with ischemic stroke were already on antiplatelet therapy, highlighting a need for trials addressing therapeutic interventions for this specific group.
Answers are grounded in this paper and cite their sources.
Common ischemic strokes despite prior antiplatelet therapy should not yet alter practice; leaves open need for targeted prevention trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Qureshi et al. (2006) conducted a cross-sectional in New or recurrent ischemic stroke (n=1,582). Previous antiplatelet drug use vs. No previous antiplatelet drug use was evaluated on Proportion of patients taking antiplatelet drugs before the onset of stroke. Previous use of antiplatelet drugs was observed in 41% (642 of 1582) of patients admitted with new or recurrent ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: